81 related articles for article (PubMed ID: 25026210)
1. Response to Chauhan et Al.: interstitial pressure and vascular collapse in pancreas cancer-fluids and solids, measurement and meaning.
DelGiorno KE; Carlson MA; Osgood R; Provenzano PP; Brockenbough JS; Thompson CB; Shepard HM; Frost GI; Potter JD; Hingorani SR
Cancer Cell; 2014 Jul; 26(1):16-7. PubMed ID: 25026210
[No Abstract] [Full Text] [Related]
2. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure.
Chauhan VP; Boucher Y; Ferrone CR; Roberge S; Martin JD; Stylianopoulos T; Bardeesy N; DePinho RA; Padera TP; Munn LL; Jain RK
Cancer Cell; 2014 Jul; 26(1):14-5. PubMed ID: 25026209
[No Abstract] [Full Text] [Related]
3. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
Provenzano PP; Cuevas C; Chang AE; Goel VK; Von Hoff DD; Hingorani SR
Cancer Cell; 2012 Mar; 21(3):418-29. PubMed ID: 22439937
[TBL] [Abstract][Full Text] [Related]
4. Complete pathological response after chemotherapy alone in a patient with pancreatic adenocarcinoma.
Carbonell S; Espinosa J; Zarco A; de-Madaria E; de la Hoz J; Yuste A; Payá A; Lluís F
Pancreas; 2012 May; 41(4):657-9. PubMed ID: 22504386
[No Abstract] [Full Text] [Related]
5. [nab-Paclitaxel as new therapeutic option for pancreatic cancer].
Michl P
Z Gastroenterol; 2013 Nov; 51(11):1329-30. PubMed ID: 24243574
[No Abstract] [Full Text] [Related]
6. A New Scalpel for the Treatment of Pancreatic Cancer: Targeting Stromal-Derived STAT3 Signaling.
Cowan RW; Maitra A; Rhim AD
Gastroenterology; 2015 Dec; 149(7):1685-8. PubMed ID: 26526714
[No Abstract] [Full Text] [Related]
7. Chemotherapy: NAPOLI-1: winning scoop for metastatic pancreatic cancer.
Hutchinson L
Nat Rev Clin Oncol; 2016 Jan; 13(1):2-3. PubMed ID: 26667974
[No Abstract] [Full Text] [Related]
8. Nanoliposomal irinotecan in metastatic pancreatic cancer.
Milosevic I; Drysdale H; Goldacre B;
Lancet; 2016 May; 387(10032):1997. PubMed ID: 27203772
[No Abstract] [Full Text] [Related]
9. Gemcitabine-resistant pancreatic cancer: a second-line option.
Oettle H; Lehmann T
Lancet; 2016 Feb; 387(10018):507-508. PubMed ID: 26616909
[No Abstract] [Full Text] [Related]
10. Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply.
Chen LT; Wang-Gillam A; Von Hoff DD; Bayever E; Belanger B
Lancet; 2016 May; 387(10032):1997. PubMed ID: 27203770
[No Abstract] [Full Text] [Related]
11. Predicting a response to FOLFIRINOX in pancreatic cancer.
Nipp RD; Ryan DP
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26025325
[No Abstract] [Full Text] [Related]
12. Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals.
Bates SE; Fojo T
Nat Rev Clin Oncol; 2016 Apr; 13(4):205-6. PubMed ID: 26902963
[No Abstract] [Full Text] [Related]
13. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
[TBL] [Abstract][Full Text] [Related]
14. Therapeutics: Disrupting a survival signal.
McCarthy N
Nat Rev Cancer; 2013 Sep; 13(9):608-9. PubMed ID: 23903094
[No Abstract] [Full Text] [Related]
15. Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?
Salvia R; Malleo G; Maggino L; Milella M; Bassi C
Updates Surg; 2020 Jun; 72(2):321-324. PubMed ID: 32445032
[No Abstract] [Full Text] [Related]
16. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
Tinchon C; Hubmann E; Pichler A; Keil F; Pichler M; Rabl H; Uggowitzer M; Jilek K; Leitner G; Bauernhofer T
Acta Oncol; 2013 Aug; 52(6):1231-3. PubMed ID: 23445338
[No Abstract] [Full Text] [Related]
17. A gut response: Modulating chemotherapy efficacy with microbial metabolites.
Bauer KC; Greten TF
Immunity; 2023 Apr; 56(4):750-752. PubMed ID: 37044066
[TBL] [Abstract][Full Text] [Related]
18. Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability.
Mondo EL; Noel MS; Katz AW; Schoeniger LO; Hezel AF
J Clin Oncol; 2013 Jan; 31(3):e37-9. PubMed ID: 23233707
[No Abstract] [Full Text] [Related]
19. Pancreatic ductal adenocarcinoma: metastatic disease.
Muñoz Martín AJ; Adeva J; Martínez-Galán J; Reina JJ; Hidalgo M
Clin Transl Oncol; 2017 Dec; 19(12):1423-1429. PubMed ID: 28623515
[TBL] [Abstract][Full Text] [Related]
20. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
